Business
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 20 29% of completed subjects with moderate to severe disease (baseline SALT
About this update from Equillium, Inc.
[{"type":"text","content":"\n20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 20\n\n\n29% of completed subjects with moderate to severe disease (baseline SALT 35 to","length":292,"tagName":"div"}]